Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | DTYMK | P23919 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412342 | 0.83 | USP30 (0.40) | BUB1POLBELANEUSP30NR1H2 | |
| SCHEMBL12035633 | 0.75 | ROCK2 (0.40) | ELANEGPR119USP30RETMAPT | |
| SCHEMBL19329675 | 0.70 | ALDH1A1 (0.43) | POLBELANESMN1; SMN2GPR119NR1H2 | |
| SCHEMBL693588 | 0.70 | FAAH (0.41) | POLBELANEUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1527234 | 0.70 | SNCA (0.30) | — | |
| SCHEMBL22951279 | 0.68 | FAAH (0.40) | POLBELANEUSP2SMN1; SMN2GPR119 | |
| SCHEMBL22501848 | 0.68 | ELANE (0.44) | POLBELANEUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1864917 | 0.68 | FAAH (0.40) | POLBELANEUSP2SMN1; SMN2GPR119 | |
| SCHEMBL3466731 | 0.68 | PDK4 (0.42) | USP2SMN1; SMN2NR1H2 | |
| SCHEMBL22233152 | 0.67 | FAAH (0.39) | POLBELANEUSP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| US-9181255-B2 | Fused heteroaromatic pyrrolidinones as SYK inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9108970-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-18 | — | — | US | disclosed |
| EP-2902392-A1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2516434-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | SYK, BTK, LYN | BUB1 1620/4885POLB 2470/4885ELANE 3642/4885 |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BUB1 1750/4885POLB 2628/4885ELANE 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.